7,650.00

+36.00

+0.47%

52,106.00

+188.00

+0.36%

28,802.50

+268.50

+0.94%

Russell 2000 Futures

2,839.30

+18.00

+0.64%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,914.70

+15.80

+0.41%

78,591.16

+926.80

+1.19%

Crude Oil Dec 26

100.67

-3.45

-3.31%

US Private Equity

10,850.63

-82.20

-0.75%

HKSE - Delayed Quote HKD

InSilico Medicine Cayman TopCo (3696.HK)

37.360 +1.360 (+3.78%)

As of 11:55:31 AM GMT+8. Market Open.

Loading Chart for 3696.HK

Chart Range Bar

Interval:

In partnership with ChartIQ

Insilico Medicine Reports 40% ORR at 130 mg for Pan-TEAD Inhibitor ISM6331 Designed Using Generative AI in Heavily Pretreated Mesothelioma at ESMO 2026

Insilico Medicine Reports 40% ORR at 130 mg for Pan-TEAD Inhibitor ISM6331 Designed Using Generative AI in Heavily Pretreated Mesothelioma at ESMO 2026

Global Longevity BioTech Market Size and Forecast Report 2026-2030 | Capitalize on 10.7% CAGR as Insilico Medicine, Calico, and Altos Labs Lead the Industry

Global Longevity BioTech Market Size and Forecast Report 2026-2030 | Capitalize on 10.7% CAGR as Insilico Medicine, Calico, and Altos Labs Lead the Industry

AI-driven Molecular Glue Innovation: Insilico Nominates ISM9546, an Oral, Peripheral-Restricted VAV1 Degrader as PCC for Autoimmune Diseases

AI-driven Molecular Glue Innovation: Insilico Nominates ISM9546, an Oral, Peripheral-Restricted VAV1 Degrader as PCC for Autoimmune Diseases

Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist

Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist

Capitalize on AI’s Drug Discovery Disruption: Benchmark NVIDIA, Schrödinger, Recursion, Insilico Medicine and Exscientia to Secure R&D ROI and Competitive Advantage Through 2030

Capitalize on AI’s Drug Discovery Disruption: Benchmark NVIDIA, Schrödinger, Recursion, Insilico Medicine and Exscientia to Secure R&D ROI and Competitive Advantage Through 2030

Insilico Medicine (SEHK:3696) Takes Its AI Discovered Drug Into Phase III Trials

Insilico Medicine (SEHK:3696) Takes Its AI Discovered Drug Into Phase III Trials

Insilico Medicine’s Alex Zhavoronkov bets China and AI can deliver the drug industry’s next breakthrough

Insilico Medicine’s Alex Zhavoronkov bets China and AI can deliver the drug industry’s next breakthrough

Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug

Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug

Artificial Intelligence (AI) for De Novo Drug Design Global Market Report 2026 | Secure 33.7% CAGR Through 2030 with Schrödinger, XtalPi, Owkin, Insilico Medicine and Recursion

Artificial Intelligence (AI) for De Novo Drug Design Global Market Report 2026 | Secure 33.7% CAGR Through 2030 with Schrödinger, XtalPi, Owkin, Insilico Medicine and Recursion

In-Silico Drug Discovery Market Report Now Available: Capitalize on AI-led R&D disruption as revenue surges from $3.3B to $6B by 2030; benchmark Certara, Insilico Medicine, Isomorphic Labs, Exscientia and BenevolentAI to secure share.

In-Silico Drug Discovery Market Report Now Available: Capitalize on AI-led R&D disruption as revenue surges from $3.3B to $6B by 2030; benchmark Certara, Insilico Medicine, Isomorphic Labs, Exscientia and BenevolentAI to secure share.

Insilico Medicine Opens AI Longevity Discovery Toolkit to Researchers Worldwide in Cell Cover Study

Insilico Medicine Opens AI Longevity Discovery Toolkit to Researchers Worldwide in Cell Cover Study

Mobilize your Website

View Site in Mobile | Classic

Share by: